The LB2102 rapid oral presentation at ASCO is a positive catalyst for Legend's solid tumor pipeline, but Phase 1 data are preliminary. Monitor the ASCO presentation (May 31) for response rates and durability. CARVYKTI's commercial momentum (18 countries, 10K+ patients) supports revenue growth but is already priced in. The Novartis partnership de-risks LB2102 development. Near-term volatility likely around ASCO data release.
Price Chart
Executive Summary
Legend Biotech announced multiple ASCO 2026 presentations, including a rapid oral presentation of preliminary Phase 1 data for LB2102 (DLL3-targeted CAR-T in SCLC/LCNEC) and new CARTITUDE-4 subgroup analyses. The LB2102 data show a manageable safety profile and early clinical activity in solid tumors, extending CAR-T beyond hematologic malignancies. CARVYKTI continues to expand commercially (18 countries, 10,000+ patients treated).
Key Facts
- Phase 1 LB2102 data in SCLC/LCNEC selected for rapid oral presentation at ASCO 2026 (Abstract #8012).
- LB2102 is a dnTGFBR2-armored DLL3-targeted CAR-T with a manageable safety profile and early clinical activity in solid tumors.
- Novartis holds exclusive worldwide license for DLL3 CAR-T therapies; Legend conducts current Phase 1, Novartis handles later development/commercialization.
- CARTITUDE-4 cytogenetic subgroup analysis (Abstract #7536) shows efficacy/safety in high- and standard-risk patients responding to bridging therapy.
- CARVYKTI approved in 18 countries, treating >10,000 patients; first and only BCMA-targeted CAR-T for multiple myeloma after ≥1 prior line.
- Investor relations event at ASCO on May 31, 2026, at 6:15 p.m. CT.
Financial Impact
No financial figures disclosed. LB2102 is early-stage (Phase 1) with no revenue; CARVYKTI commercial expansion continues but no specific sales data provided.
Risk Factors
- LB2102 is early-stage (Phase 1); solid tumor CAR-T has historically low success rates.
- CARVYKTI faces competition from other BCMA-targeted therapies (e.g., Abecma, Tecvayli).
- CARVYKTI boxed warning includes CRS, neurotoxicity, secondary malignancies; safety concerns could limit adoption.
- No financial guidance or revenue figures provided in this release.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299772 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.85 (+5.33%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.85 (+16.64%) |
Sep 29, 2026 26d ago | 144 | $18.82 | awaiting T+20 | — | $20.85 (+10.81%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.85 (+9.13%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.85 (+9.13%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.85 (+18.02%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.85 (+12.55%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.85 (−4.47%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.85 (−8.23%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.85 (+8.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers